fbpx

News

Lundbeckfonden Emerge News

Data position the company to start potential registrational trials with two drugs in two tumor types Copenhagen, Denmark – February 25, 2020: IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune modulating anti-cancer therapies based on its proprietary T-win® technology, announced the successful outcome of a scheduled interim analysis of the ongoing Phase 2 trial (IO102-012/KEYNOTE-764) of...
SAN DIEGO and COPENHAGEN, Denmark, Oct. 9, 2019 /PRNewswire/ — AFYX Therapeutics, a clinical stage biopharmaceutical company developing innovative approaches to treat mucosal diseases, today announced results from a Phase 1 clinical proof of concept study evaluating the use of the Rivelin® bio-adhesive patch in patients with vulvar lichen sclerosus (VLS), a painful genital skin condition that affects up to 3% of post-menopausal women....
In April, US investors have the opportunity to meet with 23 Danish biotech startups in New York during DKBIO 2019. Denmark already today has a thriving biotech and pharma industry fuelled by a strong academic environment, talent pool and capital. DKBIO conference on 10 and 11 April in New York provides a platform for US...
SNIPR BIOME, a leading CRISPR and microbiome private biotech company incorporated in Copenhagen, Denmark, today announced a $50 million series A financing led by existing investor Lundbeckfonden Emerge (Copenhagen) and LSP (Amsterdam), together with North-East Family Office (Copenhagen) and Wellington Partners (Munich). SNIPR BIOME is pioneering a novel use of CRISPR/Cas technology to selectively and...
Andreas Jurgeit
Andreas Jurgeit is to join Lundbeckfonden Emerge, the early stage investment unit of the Lundbeck Foundation, as a partner on 1 January 2019. Andreas has been active in various operational and financing roles over the last decade. He was first exposed to biotech as a scientist collaborating with 3V Biosciences during his PhD and later...
Copenhagen, Denmark – September 27th, 2018: IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune modulating anti-cancer therapies, based on its proprietary T-win® technology, announces that the first patient has received the first dose in an international Phase I/II clinical trial studying the investigational candidate IO102 in combination with KEYTRUDA® (pembrolizumab) for patients with non-small...
SAN DIEGO and COPENHAGEN, Denmark, July 23, 2018 /PRNewswire/ — Dermtreat, a clinical-stage biopharmaceutical company focused on mucosal diseases, today announced treatment of the first patient in a Phase 2b clinical trial of Rivelin® Clobetasol patch (Rivelin®-CLO) for oral lichen planus (OLP). Rivelin-CLO is the first biodegradable oral adhesive patch designed for local delivery of clobetasol...
Copenhagen, Denmark – August 29th, 2017: Danish-based Dermtreat today announced the GMP (Good Manufacturing Practices) approval for the production of its novel Rivelin® patch – a breakthrough therapy in treating mucosal diseases. Dermtreat has developed the Rivelin® patch – a breakthrough therapy for the treatment of mucosal diseases. Rivelin® is designed to deliver a pharmaceutical...
Copenhagen, Denmark – May 8, 2017: Danish-based Dermtreat today announced the successful closure of a USD 17.7 mill. Series A financing led by the US-based leading venture capital firm, Sofinnova, with the leading Nordic venture capital firms Novo Seeds and Lundbeckfonden Emerge in the syndicate. Existing shareholders are also participating. Dermtreat has developed the Rivelin®...
1 2 3

Lundbeckfonden Emerge

News

IO Biotech Completes Oversubscribed EUR 127 Million Series B Financing to Accelerate Clinical Programs in Oncology
13. January 2021
The Lundbeck Foundation increases its commitment to IO Biotech
12. January 2021
The Food and Drug Administration (FDA) grants IO Biotech breakthrough therapy designation for IO102 and IO103 in combination with anti-PD-1 in unresectable/ metastatic melanoma
15. December 2020